Sep 14

The Need for Nutritional Supplements – On Natural Wellness and More

In a not so environmentally friendly world, most of the soil is usually over farmed and overgrazed. Manures and other such mineral-rich products are applied scarcely on the land thus depleting it’s nutrients furthermore. This has exhausted the soil quality. Have you ever wondered what happens to soil if it is not permitted to breathe by flooding it with chemical fertilizers and toxic pesticides? Would that have an effect on the quality of the food crops that was grown on the contaminated soil? Certain research reports prolong to demonstrate that the poor quality of today’s soil is producing food crops which are deficient of vitamins and minerals.

Moreover stocking up and cooking these raw food crops further tears down its vital vitamins, minerals and digestive enzymes. Wholesome, unprocessed and organic food crops which are produced locally are proven to be the best source of nourishment. But as known to most of you, a major portion of the crop produce spends a long time traveling to the grocery store before you finally make your purchase, afterward you may store it or refrigerate it till you ultimately consume it.

Jun 01

Dr. Lori Trentacoste Battles Hearing Loss Epidemic With Prevention Seminars & Alliance

According to the NIH (National Institute of Health) about 1 in 5 Americans are suffering from hearing loss “making it the third largest health disorder in the nation next to heart disease and arthritis.”   Dr. Lori Trentacoste, head audiologist for Island Better Hearing of Long Island is one of several founding partners who founded the educational crusade for hearing impairment.  Their target groups include the Long Island construction safety agencies, hospital directors, teachers, eldercare agencies and veterans associations.  The partnership collaborates on early intervention, resources and treatment options. “Clearly, hearing loss is no longer just a problem for the aging,” states Dr. Trentacoste. “Hearing loss is common in the 18-55 age ranges because of contributions from medication side effects, stress, noise exposure and unsafe use of personal audio devices.”

Aside from her 10+ years donating time in early intervention programs in the mid-island school districts, Dr. Trentacoste is now in her second year conducting hearing loss seminars and free screening.  She is finalizing her next community presentations to take place in local libraries, private schools and health expos. (Check www.LIAHP.com for schedule)  “It is evident that so many people suffer in silence and even more have no idea how or where to get help, by reaching out on this level, it’s a comfortable place to get the facts and a proactive track to get the help they need,” says fellow audiologist and seminar co-producer, Dr. Tara Mazzone.

Trentacoste is also reaching the Long Island music community by speaking to recording artists, performers, students and retailers where awareness and prevention are in very high demand. “They say over 46% of musicians have chronic hearing disorders,” says Freeport music producer and hearing seminar staff John Rullo. “Musicians are the first targets for Tinnitus…  we all like it loud; it’s fun until you can’t hear anymore!”

Dr. Trentacoste is publishing a survival guide called “New Beginnings with Hearing Loss” and is presently directing a YouTube hearing loss video resource series.  Trentacoste has been in practice in Melville and Huntington NY for the past 28 years after taking over her father’s practice that started in the mid-seventies.  She lives in Commack, N.Y. with her husband Joseph and her two children.  She remains an active sponsor of prominent cancer organizations and is also a major supporter of the arts on Long Island.

Feb 18

Eisai’s Epilepsy Treatment Zonegran® (Zonisamide) Approved for Use in Children and Adolescents in France

On the February 9, the Transparency Commission of the French National Authority for Health (HAS) published its advice on Zonegran® (zonisamide) in its new indication for the treatment of partial seizures in adolescents and children from 6 years of age.[1] Zonisamide, a novel anti-epileptic drug (AED) with a multimodal mechanism of action and a chemical structure unrelated to any other AED, was already indicated in Europe as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; and as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults. Now, adolescents and children from 6 years of age will be able to benefit from this treatment as an adjunctive therapy.

Epilepsy is a serious neurological disorder in childhood and has long-term implications for health and well-being.[2] Around 450,000 people in France live with the condition, with over 100 new cases diagnosed each day.[3] Although epilepsy is common in paediatrics, seizure control is only achieved in two thirds of patients and many will require additional AEDs to decrease the seizure frequency.[4]

“New therapeutic options for young people with epilepsy are needed, so I am delighted to see that zonisamide can now be prescribed in France for people aged six and above,” said Dr Stéphane Auvin, Epileptologist & Child Neurology at Pediatric Neurology, Robert Debré Children Hospital, Paris. “Epilepsy has an impact on all aspects of children and their family’s lives. New, effective and well tolerated treatments that can be used in children that achieve a balance between stopping seizures and keeping side effects to a minimum are welcomed by doctors, patients and parents.”

The Zonegran license extension in paediatrics was granted by the European Commission in October 2013. This paediatric approval was based on study 312 (CATZ) published in Epilepsia in July 2013.[5] The double-blind, randomised, multicentre, placebo-controlled Phase III study showed that significantly more patients responded positively to treatment with zonisamide (50%) compared to treatment with placebo (31%), p=0.0044.[4] The overall incidence of treatment-emergent adverse events (TEAEs) was similar in patients receiving zonisamide compared to placebo.[4]

“As a research-based pharmaceutical company and a leader in epilepsy, Eisai is not only committed to bringing innovative new therapies to market, but also ensuring that we maximise the clinical benefits of our currently licensed products,” commented France Roizen, Epilepsy Brand Lead, Eisai France. “We hope that the availability of Zonegran for use in children and adolescents in France will help many young people with epilepsy gain clinical benefit from the medicine.”

The continued development of zonisamide underscores Eisai’s human health care (hhc) mission, the pharmaceutical company’s commitment to innovative solutions in prevention, cure and care for the health and wellbeing of people worldwide. Eisai is committed to the therapeutic area of epilepsy and addressing the unmet medical needs of patients with epilepsy and their families. Eisai is proud to currently market more epilepsy products in EMEA than any other pharmaceutical company.

Older posts «